No Data
Express News | Frontier Biotech: Aikenin has renewed its contract and entered the national medical insurance catalog.
Express News | Frontier Biology: Sold 70% equity of Shanghai Jianling, a wholly-owned subsidiary, and completed industrial and commercial changes.
Express News | Frontier Biotech: Subsidiary passes pharmaceutical GMP compliance inspection
Frontier Biotech (688221.SH): Aicorine has received the approval notice for the addition of maintenance therapy indications for Phase II clinical trials.
On November 5th, Frontline Bio (688221.SH) announced that the company has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, agreeing to conduct Phase II clinical trials for the newly added maintenance indication of Ekoning, a product already on the market, according to the submitted plan. Ekoning is a nationally class 1 new drug independently developed by the company. It is the world's first approved long-acting HIV fusion inhibitor with proprietary intellectual property rights in major global markets. Ekoning, when used in combination with other antiretroviral drugs, is effective against the prevalent HIV-1 virus and resistant viruses, with dosing frequencies.
Frontier Biotech (688221): Revenue steadily increased year-on-year Actively layout emerging tracks
The company released the third quarter report of 2024, with a revenue of 40.59 million yuan in 2024Q3, a year-on-year increase of +36.30%, and a non-net profit attributable to the parent company of -57.21 million yuan. The revenue for the first three quarters of 2024 was 91.64 million yuan, with a year-on-year increase of +26.
Frontier Biology: Frontier Biotech Third Quarter 2024 Report
No Data
No Data